Global Angiogenesis Therapeutic Agent Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Angiogenesis Therapeutic Agent market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Angiogenesis Therapeutic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Angiogenesis Therapeutic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Angiogenesis Therapeutic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Angiogenesis Therapeutic Agent players cover Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
LPI (LP Information)' newest research report, the “Angiogenesis Therapeutic Agent Industry Forecast” looks at past sales and reviews total world Angiogenesis Therapeutic Agent sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiogenesis Therapeutic Agent sales for 2023 through 2029. With Angiogenesis Therapeutic Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiogenesis Therapeutic Agent industry.
This Insight Report provides a comprehensive analysis of the global Angiogenesis Therapeutic Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiogenesis Therapeutic Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiogenesis Therapeutic Agent market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiogenesis Therapeutic Agent and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiogenesis Therapeutic Agent.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiogenesis Therapeutic Agent market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Angiogenesis Therapeutic Agent market?
What factors are driving Angiogenesis Therapeutic Agent market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiogenesis Therapeutic Agent market opportunities vary by end market size?
How does Angiogenesis Therapeutic Agent break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The global Angiogenesis Therapeutic Agent market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Angiogenesis Therapeutic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Angiogenesis Therapeutic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Angiogenesis Therapeutic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Angiogenesis Therapeutic Agent players cover Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
LPI (LP Information)' newest research report, the “Angiogenesis Therapeutic Agent Industry Forecast” looks at past sales and reviews total world Angiogenesis Therapeutic Agent sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiogenesis Therapeutic Agent sales for 2023 through 2029. With Angiogenesis Therapeutic Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiogenesis Therapeutic Agent industry.
This Insight Report provides a comprehensive analysis of the global Angiogenesis Therapeutic Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiogenesis Therapeutic Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiogenesis Therapeutic Agent market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiogenesis Therapeutic Agent and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiogenesis Therapeutic Agent.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiogenesis Therapeutic Agent market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Myopic Choroidal Neovascularization
- Macular Edema
- Diabetic Retinopathy
- Macular Degeneration
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Gilead Sciences, Inc.
- Eyetech Inc.
- Becton, Dickinson and Company
- Regeneron Pharmaceuticals, Inc.
- Genentech, Inc.
- Novartis AG
- Allergan plc
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Shanghai Pharmaceuticals
- Johnson & Johnson
- Pfizer
- Sun Pharma
- Otsuka Pharmaceutical Co. Ltd
- Daiichi Sankyo
- ERC Labs
- Medicom Health care
- Implandata ophthalmic products GmbH
- The Geuder Group, MORCHER GmbH
- Novamedika
What is the 10-year outlook for the global Angiogenesis Therapeutic Agent market?
What factors are driving Angiogenesis Therapeutic Agent market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiogenesis Therapeutic Agent market opportunities vary by end market size?
How does Angiogenesis Therapeutic Agent break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Angiogenesis Therapeutic Agent Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Angiogenesis Therapeutic Agent by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Angiogenesis Therapeutic Agent by Country/Region, 2018, 2022 & 2029
2.2 Angiogenesis Therapeutic Agent Segment by Type
2.2.1 Myopic Choroidal Neovascularization
2.2.2 Macular Edema
2.2.3 Diabetic Retinopathy
2.2.4 Macular Degeneration
2.3 Angiogenesis Therapeutic Agent Sales by Type
2.3.1 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
2.3.2 Global Angiogenesis Therapeutic Agent Revenue and Market Share by Type (2018-2023)
2.3.3 Global Angiogenesis Therapeutic Agent Sale Price by Type (2018-2023)
2.4 Angiogenesis Therapeutic Agent Segment by Application
2.4.1 Retail Pharmacies
2.4.2 Online Pharmacies
2.4.3 Hospital Pharmacies
2.5 Angiogenesis Therapeutic Agent Sales by Application
2.5.1 Global Angiogenesis Therapeutic Agent Sale Market Share by Application (2018-2023)
2.5.2 Global Angiogenesis Therapeutic Agent Revenue and Market Share by Application (2018-2023)
2.5.3 Global Angiogenesis Therapeutic Agent Sale Price by Application (2018-2023)
3 GLOBAL ANGIOGENESIS THERAPEUTIC AGENT BY COMPANY
3.1 Global Angiogenesis Therapeutic Agent Breakdown Data by Company
3.1.1 Global Angiogenesis Therapeutic Agent Annual Sales by Company (2018-2023)
3.1.2 Global Angiogenesis Therapeutic Agent Sales Market Share by Company (2018-2023)
3.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Company (2018-2023)
3.2.1 Global Angiogenesis Therapeutic Agent Revenue by Company (2018-2023)
3.2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2018-2023)
3.3 Global Angiogenesis Therapeutic Agent Sale Price by Company
3.4 Key Manufacturers Angiogenesis Therapeutic Agent Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Angiogenesis Therapeutic Agent Product Location Distribution
3.4.2 Players Angiogenesis Therapeutic Agent Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANGIOGENESIS THERAPEUTIC AGENT BY GEOGRAPHIC REGION
4.1 World Historic Angiogenesis Therapeutic Agent Market Size by Geographic Region (2018-2023)
4.1.1 Global Angiogenesis Therapeutic Agent Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Angiogenesis Therapeutic Agent Market Size by Country/Region (2018-2023)
4.2.1 Global Angiogenesis Therapeutic Agent Annual Sales by Country/Region (2018-2023)
4.2.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Country/Region (2018-2023)
4.3 Americas Angiogenesis Therapeutic Agent Sales Growth
4.4 APAC Angiogenesis Therapeutic Agent Sales Growth
4.5 Europe Angiogenesis Therapeutic Agent Sales Growth
4.6 Middle East & Africa Angiogenesis Therapeutic Agent Sales Growth
5 AMERICAS
5.1 Americas Angiogenesis Therapeutic Agent Sales by Country
5.1.1 Americas Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
5.1.2 Americas Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
5.2 Americas Angiogenesis Therapeutic Agent Sales by Type
5.3 Americas Angiogenesis Therapeutic Agent Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Angiogenesis Therapeutic Agent Sales by Region
6.1.1 APAC Angiogenesis Therapeutic Agent Sales by Region (2018-2023)
6.1.2 APAC Angiogenesis Therapeutic Agent Revenue by Region (2018-2023)
6.2 APAC Angiogenesis Therapeutic Agent Sales by Type
6.3 APAC Angiogenesis Therapeutic Agent Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Angiogenesis Therapeutic Agent by Country
7.1.1 Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
7.1.2 Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
7.2 Europe Angiogenesis Therapeutic Agent Sales by Type
7.3 Europe Angiogenesis Therapeutic Agent Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Angiogenesis Therapeutic Agent by Country
8.1.1 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
8.1.2 Middle East & Africa Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
8.2 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Type
8.3 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Angiogenesis Therapeutic Agent
10.3 Manufacturing Process Analysis of Angiogenesis Therapeutic Agent
10.4 Industry Chain Structure of Angiogenesis Therapeutic Agent
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Angiogenesis Therapeutic Agent Distributors
11.3 Angiogenesis Therapeutic Agent Customer
12 WORLD FORECAST REVIEW FOR ANGIOGENESIS THERAPEUTIC AGENT BY GEOGRAPHIC REGION
12.1 Global Angiogenesis Therapeutic Agent Market Size Forecast by Region
12.1.1 Global Angiogenesis Therapeutic Agent Forecast by Region (2024-2029)
12.1.2 Global Angiogenesis Therapeutic Agent Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Angiogenesis Therapeutic Agent Forecast by Type
12.7 Global Angiogenesis Therapeutic Agent Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Gilead Sciences, Inc.
13.1.1 Gilead Sciences, Inc. Company Information
13.1.2 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.1.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Gilead Sciences, Inc. Main Business Overview
13.1.5 Gilead Sciences, Inc. Latest Developments
13.2 Eyetech Inc.
13.2.1 Eyetech Inc. Company Information
13.2.2 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.2.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eyetech Inc. Main Business Overview
13.2.5 Eyetech Inc. Latest Developments
13.3 Becton, Dickinson and Company
13.3.1 Becton, Dickinson and Company Company Information
13.3.2 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.3.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Becton, Dickinson and Company Main Business Overview
13.3.5 Becton, Dickinson and Company Latest Developments
13.4 Regeneron Pharmaceuticals, Inc.
13.4.1 Regeneron Pharmaceuticals, Inc. Company Information
13.4.2 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.4.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
13.4.5 Regeneron Pharmaceuticals, Inc. Latest Developments
13.5 Genentech, Inc.
13.5.1 Genentech, Inc. Company Information
13.5.2 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.5.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Genentech, Inc. Main Business Overview
13.5.5 Genentech, Inc. Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.6.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Allergan plc
13.7.1 Allergan plc Company Information
13.7.2 Allergan plc Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.7.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Allergan plc Main Business Overview
13.7.5 Allergan plc Latest Developments
13.8 Bayer AG
13.8.1 Bayer AG Company Information
13.8.2 Bayer AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bayer AG Main Business Overview
13.8.5 Bayer AG Latest Developments
13.9 Santen Pharmaceutical Co., Ltd.
13.9.1 Santen Pharmaceutical Co., Ltd. Company Information
13.9.2 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.9.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Santen Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Santen Pharmaceutical Co., Ltd. Latest Developments
13.10 Shanghai Pharmaceuticals
13.10.1 Shanghai Pharmaceuticals Company Information
13.10.2 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.10.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Shanghai Pharmaceuticals Main Business Overview
13.10.5 Shanghai Pharmaceuticals Latest Developments
13.11 Johnson & Johnson
13.11.1 Johnson & Johnson Company Information
13.11.2 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.11.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Johnson & Johnson Main Business Overview
13.11.5 Johnson & Johnson Latest Developments
13.12 Pfizer
13.12.1 Pfizer Company Information
13.12.2 Pfizer Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.12.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Pfizer Main Business Overview
13.12.5 Pfizer Latest Developments
13.13 Sun Pharma
13.13.1 Sun Pharma Company Information
13.13.2 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.13.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Sun Pharma Main Business Overview
13.13.5 Sun Pharma Latest Developments
13.14 Otsuka Pharmaceutical Co. Ltd
13.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
13.14.2 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.14.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Otsuka Pharmaceutical Co. Ltd Main Business Overview
13.14.5 Otsuka Pharmaceutical Co. Ltd Latest Developments
13.15 Daiichi Sankyo
13.15.1 Daiichi Sankyo Company Information
13.15.2 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.15.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Daiichi Sankyo Main Business Overview
13.15.5 Daiichi Sankyo Latest Developments
13.16 ERC Labs
13.16.1 ERC Labs Company Information
13.16.2 ERC Labs Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.16.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 ERC Labs Main Business Overview
13.16.5 ERC Labs Latest Developments
13.17 Medicom Health care
13.17.1 Medicom Health care Company Information
13.17.2 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.17.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Medicom Health care Main Business Overview
13.17.5 Medicom Health care Latest Developments
13.18 Implandata ophthalmic products GmbH
13.18.1 Implandata ophthalmic products GmbH Company Information
13.18.2 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.18.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Implandata ophthalmic products GmbH Main Business Overview
13.18.5 Implandata ophthalmic products GmbH Latest Developments
13.19 The Geuder Group, MORCHER GmbH
13.19.1 The Geuder Group, MORCHER GmbH Company Information
13.19.2 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.19.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 The Geuder Group, MORCHER GmbH Main Business Overview
13.19.5 The Geuder Group, MORCHER GmbH Latest Developments
13.20 Novamedika
13.20.1 Novamedika Company Information
13.20.2 Novamedika Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.20.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Novamedika Main Business Overview
13.20.5 Novamedika Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Angiogenesis Therapeutic Agent Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Angiogenesis Therapeutic Agent by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Angiogenesis Therapeutic Agent by Country/Region, 2018, 2022 & 2029
2.2 Angiogenesis Therapeutic Agent Segment by Type
2.2.1 Myopic Choroidal Neovascularization
2.2.2 Macular Edema
2.2.3 Diabetic Retinopathy
2.2.4 Macular Degeneration
2.3 Angiogenesis Therapeutic Agent Sales by Type
2.3.1 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
2.3.2 Global Angiogenesis Therapeutic Agent Revenue and Market Share by Type (2018-2023)
2.3.3 Global Angiogenesis Therapeutic Agent Sale Price by Type (2018-2023)
2.4 Angiogenesis Therapeutic Agent Segment by Application
2.4.1 Retail Pharmacies
2.4.2 Online Pharmacies
2.4.3 Hospital Pharmacies
2.5 Angiogenesis Therapeutic Agent Sales by Application
2.5.1 Global Angiogenesis Therapeutic Agent Sale Market Share by Application (2018-2023)
2.5.2 Global Angiogenesis Therapeutic Agent Revenue and Market Share by Application (2018-2023)
2.5.3 Global Angiogenesis Therapeutic Agent Sale Price by Application (2018-2023)
3 GLOBAL ANGIOGENESIS THERAPEUTIC AGENT BY COMPANY
3.1 Global Angiogenesis Therapeutic Agent Breakdown Data by Company
3.1.1 Global Angiogenesis Therapeutic Agent Annual Sales by Company (2018-2023)
3.1.2 Global Angiogenesis Therapeutic Agent Sales Market Share by Company (2018-2023)
3.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Company (2018-2023)
3.2.1 Global Angiogenesis Therapeutic Agent Revenue by Company (2018-2023)
3.2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2018-2023)
3.3 Global Angiogenesis Therapeutic Agent Sale Price by Company
3.4 Key Manufacturers Angiogenesis Therapeutic Agent Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Angiogenesis Therapeutic Agent Product Location Distribution
3.4.2 Players Angiogenesis Therapeutic Agent Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANGIOGENESIS THERAPEUTIC AGENT BY GEOGRAPHIC REGION
4.1 World Historic Angiogenesis Therapeutic Agent Market Size by Geographic Region (2018-2023)
4.1.1 Global Angiogenesis Therapeutic Agent Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Angiogenesis Therapeutic Agent Market Size by Country/Region (2018-2023)
4.2.1 Global Angiogenesis Therapeutic Agent Annual Sales by Country/Region (2018-2023)
4.2.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Country/Region (2018-2023)
4.3 Americas Angiogenesis Therapeutic Agent Sales Growth
4.4 APAC Angiogenesis Therapeutic Agent Sales Growth
4.5 Europe Angiogenesis Therapeutic Agent Sales Growth
4.6 Middle East & Africa Angiogenesis Therapeutic Agent Sales Growth
5 AMERICAS
5.1 Americas Angiogenesis Therapeutic Agent Sales by Country
5.1.1 Americas Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
5.1.2 Americas Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
5.2 Americas Angiogenesis Therapeutic Agent Sales by Type
5.3 Americas Angiogenesis Therapeutic Agent Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Angiogenesis Therapeutic Agent Sales by Region
6.1.1 APAC Angiogenesis Therapeutic Agent Sales by Region (2018-2023)
6.1.2 APAC Angiogenesis Therapeutic Agent Revenue by Region (2018-2023)
6.2 APAC Angiogenesis Therapeutic Agent Sales by Type
6.3 APAC Angiogenesis Therapeutic Agent Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Angiogenesis Therapeutic Agent by Country
7.1.1 Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
7.1.2 Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
7.2 Europe Angiogenesis Therapeutic Agent Sales by Type
7.3 Europe Angiogenesis Therapeutic Agent Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Angiogenesis Therapeutic Agent by Country
8.1.1 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
8.1.2 Middle East & Africa Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
8.2 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Type
8.3 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Angiogenesis Therapeutic Agent
10.3 Manufacturing Process Analysis of Angiogenesis Therapeutic Agent
10.4 Industry Chain Structure of Angiogenesis Therapeutic Agent
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Angiogenesis Therapeutic Agent Distributors
11.3 Angiogenesis Therapeutic Agent Customer
12 WORLD FORECAST REVIEW FOR ANGIOGENESIS THERAPEUTIC AGENT BY GEOGRAPHIC REGION
12.1 Global Angiogenesis Therapeutic Agent Market Size Forecast by Region
12.1.1 Global Angiogenesis Therapeutic Agent Forecast by Region (2024-2029)
12.1.2 Global Angiogenesis Therapeutic Agent Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Angiogenesis Therapeutic Agent Forecast by Type
12.7 Global Angiogenesis Therapeutic Agent Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Gilead Sciences, Inc.
13.1.1 Gilead Sciences, Inc. Company Information
13.1.2 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.1.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Gilead Sciences, Inc. Main Business Overview
13.1.5 Gilead Sciences, Inc. Latest Developments
13.2 Eyetech Inc.
13.2.1 Eyetech Inc. Company Information
13.2.2 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.2.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eyetech Inc. Main Business Overview
13.2.5 Eyetech Inc. Latest Developments
13.3 Becton, Dickinson and Company
13.3.1 Becton, Dickinson and Company Company Information
13.3.2 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.3.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Becton, Dickinson and Company Main Business Overview
13.3.5 Becton, Dickinson and Company Latest Developments
13.4 Regeneron Pharmaceuticals, Inc.
13.4.1 Regeneron Pharmaceuticals, Inc. Company Information
13.4.2 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.4.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
13.4.5 Regeneron Pharmaceuticals, Inc. Latest Developments
13.5 Genentech, Inc.
13.5.1 Genentech, Inc. Company Information
13.5.2 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.5.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Genentech, Inc. Main Business Overview
13.5.5 Genentech, Inc. Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.6.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Allergan plc
13.7.1 Allergan plc Company Information
13.7.2 Allergan plc Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.7.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Allergan plc Main Business Overview
13.7.5 Allergan plc Latest Developments
13.8 Bayer AG
13.8.1 Bayer AG Company Information
13.8.2 Bayer AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bayer AG Main Business Overview
13.8.5 Bayer AG Latest Developments
13.9 Santen Pharmaceutical Co., Ltd.
13.9.1 Santen Pharmaceutical Co., Ltd. Company Information
13.9.2 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.9.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Santen Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Santen Pharmaceutical Co., Ltd. Latest Developments
13.10 Shanghai Pharmaceuticals
13.10.1 Shanghai Pharmaceuticals Company Information
13.10.2 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.10.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Shanghai Pharmaceuticals Main Business Overview
13.10.5 Shanghai Pharmaceuticals Latest Developments
13.11 Johnson & Johnson
13.11.1 Johnson & Johnson Company Information
13.11.2 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.11.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Johnson & Johnson Main Business Overview
13.11.5 Johnson & Johnson Latest Developments
13.12 Pfizer
13.12.1 Pfizer Company Information
13.12.2 Pfizer Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.12.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Pfizer Main Business Overview
13.12.5 Pfizer Latest Developments
13.13 Sun Pharma
13.13.1 Sun Pharma Company Information
13.13.2 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.13.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Sun Pharma Main Business Overview
13.13.5 Sun Pharma Latest Developments
13.14 Otsuka Pharmaceutical Co. Ltd
13.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
13.14.2 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.14.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Otsuka Pharmaceutical Co. Ltd Main Business Overview
13.14.5 Otsuka Pharmaceutical Co. Ltd Latest Developments
13.15 Daiichi Sankyo
13.15.1 Daiichi Sankyo Company Information
13.15.2 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.15.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Daiichi Sankyo Main Business Overview
13.15.5 Daiichi Sankyo Latest Developments
13.16 ERC Labs
13.16.1 ERC Labs Company Information
13.16.2 ERC Labs Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.16.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 ERC Labs Main Business Overview
13.16.5 ERC Labs Latest Developments
13.17 Medicom Health care
13.17.1 Medicom Health care Company Information
13.17.2 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.17.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Medicom Health care Main Business Overview
13.17.5 Medicom Health care Latest Developments
13.18 Implandata ophthalmic products GmbH
13.18.1 Implandata ophthalmic products GmbH Company Information
13.18.2 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.18.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Implandata ophthalmic products GmbH Main Business Overview
13.18.5 Implandata ophthalmic products GmbH Latest Developments
13.19 The Geuder Group, MORCHER GmbH
13.19.1 The Geuder Group, MORCHER GmbH Company Information
13.19.2 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.19.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 The Geuder Group, MORCHER GmbH Main Business Overview
13.19.5 The Geuder Group, MORCHER GmbH Latest Developments
13.20 Novamedika
13.20.1 Novamedika Company Information
13.20.2 Novamedika Angiogenesis Therapeutic Agent Product Portfolios and Specifications
13.20.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Novamedika Main Business Overview
13.20.5 Novamedika Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Angiogenesis Therapeutic Agent Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Angiogenesis Therapeutic Agent Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Myopic Choroidal Neovascularization
Table 4. Major Players of Macular Edema
Table 5. Major Players of Diabetic Retinopathy
Table 6. Major Players of Macular Degeneration
Table 7. Global Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 8. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Table 9. Global Angiogenesis Therapeutic Agent Revenue by Type (2018-2023) & ($ million)
Table 10. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2023)
Table 11. Global Angiogenesis Therapeutic Agent Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 13. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Table 14. Global Angiogenesis Therapeutic Agent Revenue by Application (2018-2023)
Table 15. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2023)
Table 16. Global Angiogenesis Therapeutic Agent Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Angiogenesis Therapeutic Agent Sales by Company (2018-2023) & (K Units)
Table 18. Global Angiogenesis Therapeutic Agent Sales Market Share by Company (2018-2023)
Table 19. Global Angiogenesis Therapeutic Agent Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2018-2023)
Table 21. Global Angiogenesis Therapeutic Agent Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Angiogenesis Therapeutic Agent Producing Area Distribution and Sales Area
Table 23. Players Angiogenesis Therapeutic Agent Products Offered
Table 24. Angiogenesis Therapeutic Agent Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Angiogenesis Therapeutic Agent Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Angiogenesis Therapeutic Agent Sales Market Share Geographic Region (2018-2023)
Table 29. Global Angiogenesis Therapeutic Agent Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Angiogenesis Therapeutic Agent Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Angiogenesis Therapeutic Agent Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Angiogenesis Therapeutic Agent Sales Market Share by Country/Region (2018-2023)
Table 33. Global Angiogenesis Therapeutic Agent Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Angiogenesis Therapeutic Agent Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)
Table 36. Americas Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)
Table 37. Americas Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)
Table 39. Americas Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 40. Americas Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 41. APAC Angiogenesis Therapeutic Agent Sales by Region (2018-2023) & (K Units)
Table 42. APAC Angiogenesis Therapeutic Agent Sales Market Share by Region (2018-2023)
Table 43. APAC Angiogenesis Therapeutic Agent Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Angiogenesis Therapeutic Agent Revenue Market Share by Region (2018-2023)
Table 45. APAC Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 46. APAC Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 47. Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)
Table 48. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)
Table 49. Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)
Table 51. Europe Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 52. Europe Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Angiogenesis Therapeutic Agent
Table 60. Key Market Challenges & Risks of Angiogenesis Therapeutic Agent
Table 61. Key Industry Trends of Angiogenesis Therapeutic Agent
Table 62. Angiogenesis Therapeutic Agent Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Angiogenesis Therapeutic Agent Distributors List
Table 65. Angiogenesis Therapeutic Agent Customer List
Table 66. Global Angiogenesis Therapeutic Agent Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Angiogenesis Therapeutic Agent Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Angiogenesis Therapeutic Agent Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Angiogenesis Therapeutic Agent Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Angiogenesis Therapeutic Agent Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Angiogenesis Therapeutic Agent Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Angiogenesis Therapeutic Agent Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Angiogenesis Therapeutic Agent Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Gilead Sciences, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 81. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 82. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Gilead Sciences, Inc. Main Business
Table 84. Gilead Sciences, Inc. Latest Developments
Table 85. Eyetech Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 86. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 87. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Eyetech Inc. Main Business
Table 89. Eyetech Inc. Latest Developments
Table 90. Becton, Dickinson and Company Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 91. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 92. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Becton, Dickinson and Company Main Business
Table 94. Becton, Dickinson and Company Latest Developments
Table 95. Regeneron Pharmaceuticals, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 96. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 97. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Regeneron Pharmaceuticals, Inc. Main Business
Table 99. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 100. Genentech, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 101. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 102. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Genentech, Inc. Main Business
Table 104. Genentech, Inc. Latest Developments
Table 105. Novartis AG Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 106. Novartis AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 107. Novartis AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Novartis AG Main Business
Table 109. Novartis AG Latest Developments
Table 110. Allergan plc Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 111. Allergan plc Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 112. Allergan plc Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Allergan plc Main Business
Table 114. Allergan plc Latest Developments
Table 115. Bayer AG Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 116. Bayer AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 117. Bayer AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Bayer AG Main Business
Table 119. Bayer AG Latest Developments
Table 120. Santen Pharmaceutical Co., Ltd. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 121. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 122. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Santen Pharmaceutical Co., Ltd. Main Business
Table 124. Santen Pharmaceutical Co., Ltd. Latest Developments
Table 125. Shanghai Pharmaceuticals Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 126. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 127. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Shanghai Pharmaceuticals Main Business
Table 129. Shanghai Pharmaceuticals Latest Developments
Table 130. Johnson & Johnson Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 131. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 132. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Johnson & Johnson Main Business
Table 134. Johnson & Johnson Latest Developments
Table 135. Pfizer Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 136. Pfizer Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 137. Pfizer Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Pfizer Main Business
Table 139. Pfizer Latest Developments
Table 140. Sun Pharma Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 141. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 142. Sun Pharma Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Sun Pharma Main Business
Table 144. Sun Pharma Latest Developments
Table 145. Otsuka Pharmaceutical Co. Ltd Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 146. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 147. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Otsuka Pharmaceutical Co. Ltd Main Business
Table 149. Otsuka Pharmaceutical Co. Ltd Latest Developments
Table 150. Daiichi Sankyo Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 151. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 152. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Daiichi Sankyo Main Business
Table 154. Daiichi Sankyo Latest Developments
Table 155. ERC Labs Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 156. ERC Labs Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 157. ERC Labs Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. ERC Labs Main Business
Table 159. ERC Labs Latest Developments
Table 160. Medicom Health care Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 161. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 162. Medicom Health care Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Medicom Health care Main Business
Table 164. Medicom Health care Latest Developments
Table 165. Implandata ophthalmic products GmbH Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 166. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 167. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 168. Implandata ophthalmic products GmbH Main Business
Table 169. Implandata ophthalmic products GmbH Latest Developments
Table 170. The Geuder Group, MORCHER GmbH Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 171. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 172. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 173. The Geuder Group, MORCHER GmbH Main Business
Table 174. The Geuder Group, MORCHER GmbH Latest Developments
Table 175. Novamedika Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 176. Novamedika Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 177. Novamedika Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 178. Novamedika Main Business
Table 179. Novamedika Latest Developments
Table 1. Angiogenesis Therapeutic Agent Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Angiogenesis Therapeutic Agent Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Myopic Choroidal Neovascularization
Table 4. Major Players of Macular Edema
Table 5. Major Players of Diabetic Retinopathy
Table 6. Major Players of Macular Degeneration
Table 7. Global Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 8. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Table 9. Global Angiogenesis Therapeutic Agent Revenue by Type (2018-2023) & ($ million)
Table 10. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2023)
Table 11. Global Angiogenesis Therapeutic Agent Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 13. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Table 14. Global Angiogenesis Therapeutic Agent Revenue by Application (2018-2023)
Table 15. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2023)
Table 16. Global Angiogenesis Therapeutic Agent Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Angiogenesis Therapeutic Agent Sales by Company (2018-2023) & (K Units)
Table 18. Global Angiogenesis Therapeutic Agent Sales Market Share by Company (2018-2023)
Table 19. Global Angiogenesis Therapeutic Agent Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2018-2023)
Table 21. Global Angiogenesis Therapeutic Agent Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Angiogenesis Therapeutic Agent Producing Area Distribution and Sales Area
Table 23. Players Angiogenesis Therapeutic Agent Products Offered
Table 24. Angiogenesis Therapeutic Agent Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Angiogenesis Therapeutic Agent Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Angiogenesis Therapeutic Agent Sales Market Share Geographic Region (2018-2023)
Table 29. Global Angiogenesis Therapeutic Agent Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Angiogenesis Therapeutic Agent Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Angiogenesis Therapeutic Agent Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Angiogenesis Therapeutic Agent Sales Market Share by Country/Region (2018-2023)
Table 33. Global Angiogenesis Therapeutic Agent Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Angiogenesis Therapeutic Agent Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)
Table 36. Americas Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)
Table 37. Americas Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)
Table 39. Americas Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 40. Americas Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 41. APAC Angiogenesis Therapeutic Agent Sales by Region (2018-2023) & (K Units)
Table 42. APAC Angiogenesis Therapeutic Agent Sales Market Share by Region (2018-2023)
Table 43. APAC Angiogenesis Therapeutic Agent Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Angiogenesis Therapeutic Agent Revenue Market Share by Region (2018-2023)
Table 45. APAC Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 46. APAC Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 47. Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)
Table 48. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)
Table 49. Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)
Table 51. Europe Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 52. Europe Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Angiogenesis Therapeutic Agent
Table 60. Key Market Challenges & Risks of Angiogenesis Therapeutic Agent
Table 61. Key Industry Trends of Angiogenesis Therapeutic Agent
Table 62. Angiogenesis Therapeutic Agent Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Angiogenesis Therapeutic Agent Distributors List
Table 65. Angiogenesis Therapeutic Agent Customer List
Table 66. Global Angiogenesis Therapeutic Agent Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Angiogenesis Therapeutic Agent Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Angiogenesis Therapeutic Agent Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Angiogenesis Therapeutic Agent Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Angiogenesis Therapeutic Agent Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Angiogenesis Therapeutic Agent Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Angiogenesis Therapeutic Agent Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Angiogenesis Therapeutic Agent Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Gilead Sciences, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 81. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 82. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Gilead Sciences, Inc. Main Business
Table 84. Gilead Sciences, Inc. Latest Developments
Table 85. Eyetech Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 86. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 87. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Eyetech Inc. Main Business
Table 89. Eyetech Inc. Latest Developments
Table 90. Becton, Dickinson and Company Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 91. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 92. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Becton, Dickinson and Company Main Business
Table 94. Becton, Dickinson and Company Latest Developments
Table 95. Regeneron Pharmaceuticals, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 96. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 97. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Regeneron Pharmaceuticals, Inc. Main Business
Table 99. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 100. Genentech, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 101. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 102. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Genentech, Inc. Main Business
Table 104. Genentech, Inc. Latest Developments
Table 105. Novartis AG Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 106. Novartis AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 107. Novartis AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Novartis AG Main Business
Table 109. Novartis AG Latest Developments
Table 110. Allergan plc Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 111. Allergan plc Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 112. Allergan plc Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Allergan plc Main Business
Table 114. Allergan plc Latest Developments
Table 115. Bayer AG Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 116. Bayer AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 117. Bayer AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Bayer AG Main Business
Table 119. Bayer AG Latest Developments
Table 120. Santen Pharmaceutical Co., Ltd. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 121. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 122. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Santen Pharmaceutical Co., Ltd. Main Business
Table 124. Santen Pharmaceutical Co., Ltd. Latest Developments
Table 125. Shanghai Pharmaceuticals Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 126. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 127. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Shanghai Pharmaceuticals Main Business
Table 129. Shanghai Pharmaceuticals Latest Developments
Table 130. Johnson & Johnson Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 131. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 132. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Johnson & Johnson Main Business
Table 134. Johnson & Johnson Latest Developments
Table 135. Pfizer Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 136. Pfizer Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 137. Pfizer Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Pfizer Main Business
Table 139. Pfizer Latest Developments
Table 140. Sun Pharma Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 141. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 142. Sun Pharma Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Sun Pharma Main Business
Table 144. Sun Pharma Latest Developments
Table 145. Otsuka Pharmaceutical Co. Ltd Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 146. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 147. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Otsuka Pharmaceutical Co. Ltd Main Business
Table 149. Otsuka Pharmaceutical Co. Ltd Latest Developments
Table 150. Daiichi Sankyo Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 151. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 152. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Daiichi Sankyo Main Business
Table 154. Daiichi Sankyo Latest Developments
Table 155. ERC Labs Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 156. ERC Labs Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 157. ERC Labs Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. ERC Labs Main Business
Table 159. ERC Labs Latest Developments
Table 160. Medicom Health care Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 161. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 162. Medicom Health care Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Medicom Health care Main Business
Table 164. Medicom Health care Latest Developments
Table 165. Implandata ophthalmic products GmbH Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 166. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 167. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 168. Implandata ophthalmic products GmbH Main Business
Table 169. Implandata ophthalmic products GmbH Latest Developments
Table 170. The Geuder Group, MORCHER GmbH Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 171. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 172. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 173. The Geuder Group, MORCHER GmbH Main Business
Table 174. The Geuder Group, MORCHER GmbH Latest Developments
Table 175. Novamedika Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
Table 176. Novamedika Angiogenesis Therapeutic Agent Product Portfolios and Specifications
Table 177. Novamedika Angiogenesis Therapeutic Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 178. Novamedika Main Business
Table 179. Novamedika Latest Developments
LIST OF FIGURES
Figure 1. Picture of Angiogenesis Therapeutic Agent
Figure 2. Angiogenesis Therapeutic Agent Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Angiogenesis Therapeutic Agent Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Angiogenesis Therapeutic Agent Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Angiogenesis Therapeutic Agent Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Myopic Choroidal Neovascularization
Figure 10. Product Picture of Macular Edema
Figure 11. Product Picture of Diabetic Retinopathy
Figure 12. Product Picture of Macular Degeneration
Figure 13. Global Angiogenesis Therapeutic Agent Sales Market Share by Type in 2022
Figure 14. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2023)
Figure 15. Angiogenesis Therapeutic Agent Consumed in Retail Pharmacies
Figure 16. Global Angiogenesis Therapeutic Agent Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 17. Angiogenesis Therapeutic Agent Consumed in Online Pharmacies
Figure 18. Global Angiogenesis Therapeutic Agent Market: Online Pharmacies (2018-2023) & (K Units)
Figure 19. Angiogenesis Therapeutic Agent Consumed in Hospital Pharmacies
Figure 20. Global Angiogenesis Therapeutic Agent Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 21. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2022)
Figure 22. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application in 2022
Figure 23. Angiogenesis Therapeutic Agent Sales Market by Company in 2022 (K Units)
Figure 24. Global Angiogenesis Therapeutic Agent Sales Market Share by Company in 2022
Figure 25. Angiogenesis Therapeutic Agent Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company in 2022
Figure 27. Global Angiogenesis Therapeutic Agent Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Angiogenesis Therapeutic Agent Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 30. Americas Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 31. APAC Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 32. APAC Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 33. Europe Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 34. Europe Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 37. Americas Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
Figure 38. Americas Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
Figure 39. Americas Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 40. Americas Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 41. United States Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Angiogenesis Therapeutic Agent Sales Market Share by Region in 2022
Figure 46. APAC Angiogenesis Therapeutic Agent Revenue Market Share by Regions in 2022
Figure 47. APAC Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 48. APAC Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 49. China Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
Figure 57. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
Figure 58. Europe Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 59. Europe Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 60. Germany Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 69. Egypt Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Angiogenesis Therapeutic Agent in 2022
Figure 75. Manufacturing Process Analysis of Angiogenesis Therapeutic Agent
Figure 76. Industry Chain Structure of Angiogenesis Therapeutic Agent
Figure 77. Channels of Distribution
Figure 78. Global Angiogenesis Therapeutic Agent Sales Market Forecast by Region (2024-2029)
Figure 79. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Angiogenesis Therapeutic Agent Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Angiogenesis Therapeutic Agent Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Angiogenesis Therapeutic Agent
Figure 2. Angiogenesis Therapeutic Agent Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Angiogenesis Therapeutic Agent Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Angiogenesis Therapeutic Agent Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Angiogenesis Therapeutic Agent Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Myopic Choroidal Neovascularization
Figure 10. Product Picture of Macular Edema
Figure 11. Product Picture of Diabetic Retinopathy
Figure 12. Product Picture of Macular Degeneration
Figure 13. Global Angiogenesis Therapeutic Agent Sales Market Share by Type in 2022
Figure 14. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2023)
Figure 15. Angiogenesis Therapeutic Agent Consumed in Retail Pharmacies
Figure 16. Global Angiogenesis Therapeutic Agent Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 17. Angiogenesis Therapeutic Agent Consumed in Online Pharmacies
Figure 18. Global Angiogenesis Therapeutic Agent Market: Online Pharmacies (2018-2023) & (K Units)
Figure 19. Angiogenesis Therapeutic Agent Consumed in Hospital Pharmacies
Figure 20. Global Angiogenesis Therapeutic Agent Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 21. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2022)
Figure 22. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application in 2022
Figure 23. Angiogenesis Therapeutic Agent Sales Market by Company in 2022 (K Units)
Figure 24. Global Angiogenesis Therapeutic Agent Sales Market Share by Company in 2022
Figure 25. Angiogenesis Therapeutic Agent Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company in 2022
Figure 27. Global Angiogenesis Therapeutic Agent Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Angiogenesis Therapeutic Agent Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 30. Americas Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 31. APAC Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 32. APAC Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 33. Europe Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 34. Europe Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Angiogenesis Therapeutic Agent Revenue 2018-2023 ($ Millions)
Figure 37. Americas Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
Figure 38. Americas Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
Figure 39. Americas Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 40. Americas Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 41. United States Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Angiogenesis Therapeutic Agent Sales Market Share by Region in 2022
Figure 46. APAC Angiogenesis Therapeutic Agent Revenue Market Share by Regions in 2022
Figure 47. APAC Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 48. APAC Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 49. China Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
Figure 57. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
Figure 58. Europe Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 59. Europe Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 60. Germany Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
Figure 69. Egypt Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Angiogenesis Therapeutic Agent in 2022
Figure 75. Manufacturing Process Analysis of Angiogenesis Therapeutic Agent
Figure 76. Industry Chain Structure of Angiogenesis Therapeutic Agent
Figure 77. Channels of Distribution
Figure 78. Global Angiogenesis Therapeutic Agent Sales Market Forecast by Region (2024-2029)
Figure 79. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Angiogenesis Therapeutic Agent Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Angiogenesis Therapeutic Agent Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Application (2024-2029)
